Boron Compound Active Ingredients TRIZ Cases

Inhaled arginase inhibitor ABH reverses airway hyperresponsiveness by increasing nitric oxide production, preventing early and late asthmatic reactions.

Bicyclic derivatives overcome macrocyclic lactone resistance by introducing heteroaryl groups at the C-1 position.

Replacing aspartic acid in peptide structures eliminates calcium dependency, enabling potent antibacterial activity against drug-resistant bacteria.

Modulating 19S proteasome subunit expression overcomes acquired resistance in hematopoietic tumors, restoring treatment effectiveness.

Boronic acid functionalization on the liphagane scaffold enables specific PI3K inhibition, resolving poor selectivity and stability of prior inhibitors.

Cholic acid 7-sulfate activates hepatic vitamin D receptor to induce bile acid sulfotransferase, offering non-invasive metabolic disorder treatment.

HDAC6 inhibitors activate T-cells to boost anti-tumor immune responses, overcoming limited targeting in current cancer immunotherapies.

Propylene glycol solvents suppress oxidative degradation, maintaining bortezomib stability for multi-dose storage applications.

Removing butylated hydroxytoluene from the oxaborolan excipient mix resolves phase separation and chemical instability.

Dicycloplatin composite resolves aqueous instability and limited efficacy by joining carboplatin with cyclobutane dicarboxylate.

A polyaphron dispersion topical composition maintains crisaborole solubility and stability within a biphasic aqueous-oil system.

Modified patentiflorin A analogs deliver broad-spectrum antiviral efficacy while reducing host toxicity and addressing drug resistance.

Formula I compounds inhibit arginase to restore arginine levels, enhancing cytotoxic T-cell activation and anti-tumor immune responses.

Segmented SDC-TRAP compounds bind Hsp90 to deliver cytotoxic effectors, reducing systemic toxicity while retaining therapeutic agents in target cells.